Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S-740792 in healthy volunteers
NCT06724978Phase 1Completed
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Nov 2024
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of S-740792 (3 arms), sponsored by Shionogi & Co., Ltd. Primary endpoints: Treatment-emergent Adverse Events at 28 days, Plasma Concentration of S-740792 at 144 hours and 1 more. Started Nov 2024; status: completed.
02
Drugs
S-740792
Beyond the preview
Go deeper on NCT06724978.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06724978.